Results 141 to 150 of about 6,730 (183)
Some of the next articles are maybe not open access.
Thrombopoietin-receptor agonists
Current Opinion in Hematology, 2012Thrombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy. There is increasing interest to expand the role of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.In ITP, more studies are providing evidence of TPO-RA efficacy and safety, as well as their ...
Paul A, Basciano, James B, Bussel
openaire +2 more sources
c-mpl, the Thrombopoietin Receptor
Thrombosis and Haemostasis, 1995v-mpl is a mouse oncogene that is part of the genome of the myeloproliferative leukemia virus (MPLV). The cellular homolog gene c-mpl encodes an hematopoietic cytokine receptor mainly restricted to the megakaryocytic lineage of differentiation. Using the Mpl receptor protein, cDNAs corresponding to the receptor ligand were isolated in humans, pigs ...
W, Vainchenker +4 more
openaire +2 more sources
Thrombopoietin Receptor Agonists: A Critical Review
Seminars in Hematology, 2015Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging ...
William B, Mitchell, James B, Bussel
openaire +2 more sources
Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia
New England Journal of Medicine, 2011To the Editor: In response to the review by Imbach and Crowther (Aug. 25 issue)1 of thrombopoietin-receptor agonists for primary immune thrombocytopenia: we would like to draw attention to the fact...
Jansen, Gerard +2 more
openaire +3 more sources
Transfusion, 2002
BACKGROUND: Data from several studies support the hypothesis that thrombopoietin (TPO) plasma levels are regulated via circulating platelet (PLT) numbers by binding to PLT TPO receptors (TPO‐Rs). In this study, PLT numbers and TPO plasma levels were measured following the transfusion of unmanipulated, sham‐saturated, and TPO‐R‐saturated PLT ...
Stefan, Scheding +8 more
openaire +2 more sources
BACKGROUND: Data from several studies support the hypothesis that thrombopoietin (TPO) plasma levels are regulated via circulating platelet (PLT) numbers by binding to PLT TPO receptors (TPO‐Rs). In this study, PLT numbers and TPO plasma levels were measured following the transfusion of unmanipulated, sham‐saturated, and TPO‐R‐saturated PLT ...
Stefan, Scheding +8 more
openaire +2 more sources
Thrombopoietin receptor agonists in the treatment of thrombocytopenia
Current Opinion in Hematology, 2009The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific immune suppression designed to reduce platelet destruction. As a consequence, at least half of the morbidity and mortality in this condition is related to infection secondary to treatment, and alternative treatments are desirable.It has been shown ...
openaire +2 more sources
Thrombopoietin and its receptor.
European cytokine network, 1999Thrombopoietin (TPO), the primary physiological regulator of platelet production, was initially thought to be a lineage-specific factor acting predominantly on megakaryocytopoiesis. Detailed studies establish that this cytokine mediates biological effects on a broad spectrum of hematopoietic progenitor cells, including stem cells.
F, Wendling, W, Vainchenker
openaire +1 more source
The pharmacology and clinical application of thrombopoietin receptor agonists
International Journal of Hematology, 2014The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy).
Caizheng, Li, Li, Zheng
openaire +2 more sources
The Role of the Thrombopoietin Receptor in Megakaryopoiesis
2001Abstract Occasionally, in science, findings from one area of researchinsightful and important for that discipline-exert a profound, catalytic influence on what was previously thought to be a completely unrelated field of study. The discovery of the oncogene v-mpl was such an event, initiating a new chapter in the study of hematopoietic ...
Jonathan G Drachman, Kenneth Kaushansky
openaire +1 more source
Thrombopoietin Receptor Agonists
2017Thrombopoietin receptor agonists (TPO-RAs) should be considered for the treatment of “refractory” autoimmune thrombocytopenia (ITP). In contrast to other medications, TPO-RAs increase platelets via stimulating the production of megakaryocytes/platelets in the bone marrow. This chapter has dealt with the mechanism, efficacy, and safety of TPO-RAs.
openaire +1 more source